CRC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CRC is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 who is unwilling to wait for a better entry. The stock has some bullish fundamental and sentiment support from analyst Buy/Outperform ratings, heavy hedge fund buying, and positive congress buying, but the short-term technical setup is weak and the current price is sitting right at support with negative momentum. I would not call this a clear buy today; the better call is to hold and wait for confirmation of a rebound above resistance.
CRC closed at 51.26, essentially on the S1 support at 51.35 and just above S2 at 50.155. RSI_6 is 19.221, which is deeply oversold, but the MACD histogram is -0.245 and still expanding negatively, showing downside momentum is still active. Moving averages are converging, which often signals a possible turning point, but not a confirmed one. The pattern data also suggests weakness, with a 60% chance of declines over the next day, week, and month. Overall, the technical picture is oversold but not yet bullish.
Analysts remain generally constructive, with Citi, Barclays, Mizuho, UBS, and BofA all maintaining positive ratings and several raising targets. Hedge funds are reported as buying aggressively, up 106.76% over the last quarter. Congress trading data is also positive, with 1 purchase transaction and no sales, totaling roughly $5M-$10M. The stock may also benefit if oil prices stay supportive, since multiple analyst notes point to a favorable medium-term oil backdrop.
There was no new news in the past week to create an immediate catalyst. Citi recently lowered its target from $78 to $70, signaling some moderation in upside expectations. The stock is showing weak short-term price action with negative MACD momentum, and the pattern-based trend outlook points to a likely decline over the near term. The broader market was also slightly weak, with the S&P 500 down 0.13%.
No usable latest-quarter financial snapshot was provided, so I cannot assess revenue, earnings, or margins for the most recent quarter season. Based on the data available, there is no current financial release to support a fresh fundamental improvement thesis.
Wall Street remains positive overall: Citi rates Buy with a $70 target after cutting it from $78, Mizuho has Outperform with an $87 target, Barclays has Overweight with an $80 target, UBS has Buy with a $78 target, and BofA has Buy with a $77 target. The pros view is that CRC has leverage to oil and remains attractively valued relative to medium-term crude expectations. The main con is that some targets have recently been trimmed, showing reduced upside enthusiasm as Brent prices softened.
